CXCL1 and arthritic joint disease: This was supported by the findings that like MTX, treatment with CS12192 significantly reduced the arthritis score, X-ray score and serum levels of RF, CRP and ANA, and improved the histopathological damage and joint inflammation, as well as the expression of inflammatory cytokines and chemokines such as IL-1β, TNF-α, IL-6, CCL2, and CXCL1.